Hi, APhA–ASP! It is an immense honor to serve you as the 2024–2025 APhA–ASP national president-elect. Thank you for trusting me to represent you, advocate for you, and support you as you lead your chapters and serve your communities.

With a cool spring breeze on a bright, sunny Sunday, the Sunshine State pulled out all the stops to make the third day of the 2024 APhA Annual Meeting & Exposition (March 24) a beautiful one.

In a new study published in The BMJ, researchers found that using two new classes of T2D drugs together yielded benefits. When study participants took GLP-1 receptor agonists therapy added to a SGLT-2 inhibitor, they curtailed their risk of major adverse cardiovascular events by about 30% compared with taking an agent from just one class. The likelihood for serious renal events was also lower with combination therapy.